Thyroxine administration during radiation therapy to the neck does not prevent subsequent thyroid dysfunction.
In an attempt to reduce the incidence of hypothyroidism following irradiation of the neck, we administered oral L-thyroxine in doses sufficient to suppress serum TSH to 20 patients receiving radiation therapy for Hodgkin's disease or other lymphomas. L-thyroxine was discontinued when radiation therapy was completed. Twenty similar patients who did not receive L-thyroxine during radiation therapy served as a control group. After a mean follow-up period of 33 months, seven patients (35%) in the L-thyroxine group developed elevation of serum TSH and were started on chronic L-thyroxine therapy. In the control group, after mean follow-up of 19 months, five patients (25%) developed elevation of TSH and were started on chronic L-thyroxine. We conclude that suppression of serum TSH during neck irradiation does not prevent subsequent thyroid dysfunction.
D000293:Adolescent; D000328:Adult; D005260:Female; D006689:Hodgkin Disease / Q000532:radiotherapy*; D006801:Humans; D007037:Hypothyroidism / Q000209:etiology / Q000517:prevention & control*; D008223:Lymphoma / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009333:Neck / Q000528:radiation effects; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000627:therapeutic use*
D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; D013974:Thyroxine